

Please see the detail information below, as required by Vermont legislation for Biocon Pharma, Inc regarding new product launch for Everolimus tablets.

1. A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally:
  - a. **Launch of a generic pharmaceutical. Pricing and supply offers made to large GPOs with purchasing decision authority for retail, wholesale, and specialty outlets. GPOs include Red Oak Sourcing, Walgreens Boots Alliance Development, ClarusONE Sourcing Services, and Econdisc. Biocon will offer an eVoucherRx program to lower patient co-pays at the point of sale.**
2. The estimated volume of patients who may be prescribed the drug;
  - a. **About 13,000 patients per year treated with Everolimus tablets 2.5mg, 5mg, 7.5mg and 10mg**
3. Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval; and –
  - a. **No**
4. The date and price of acquisition if the drug was not developed by the manufacturer –
  - a. **N/A – drug developed internally.**